News Release
VIVIO Extends Open Market Specialty Drug Platform to Solve Our PBM Crisis
VIVIO announces PrecisionCare One™, an extension of its proven open-market specialty drug management platform to include all drugs
Read News Release

Free Your Company From a System Designed to Cost You More

Break free from the 'PBM tax' with VIVIO's open market model. By leveraging data intelligence to personalize drug therapies, we deliver lower prescription drug costs, providing your plan members with the care they deserve.

Experience True Drug Management with VIVIO

VIVIO redefines drug management by using data intelligence and a transparent, adaptable model that ensures optimal outcomes at the most competitive prices. Unlike PBM models which are driven by profit, VIVIO leverages data from clinical trials, individual patient needs, and market prices to provide personalized drug therapies. Our innovative software seamlessly integrates these elements to deliver the right drug for the right patient at the right price, eliminating unnecessary middlemen and markups. Access a broader range of drug therapies, achieve substantial cost savings, and provide better care with VIVIO.

Right Drug

Right Patient

Right Price

Right Thing To Do

VIVIO

Analyzes clinical trial data, and independently classifies drugs based on effectiveness.

Personalized Drug Therapies based on the patient's unique medical history.

Open Market to access lower prices wherever they are available.

Employers own their data and meet their fiduciary obligations through unfettered access to VIVIO & Market Data.

PBM Model

Blindly relies on FDA approvals and guidelines instead of underlying data.

Prior Authorizations based on Formularies.

"Black Box" drug pricing to limit access and maximize their profit.

Withholds data and exposes employers to Fiduciary risk.

Tailored Drug Therapy for Every Individual

Discover how our innovative approach ensures that every individual receives the right therapy, tailored specifically to their unique needs, all at a fair cost. In this video, we explore how our commitment to personalized care and transparency is pricing revolutionizes the healthcare experience, making top-quality treatment accessible and affordable for everyone, every time.

Watch Video

F1000 Public Company Saved $14.8 Million

"Finding, and then hiring VIVIO in 2019 was one of the best decisions I've made in my 44-year career. Our experience as a VIVIO customer prior to and post-launch has been incredibly positive."

-John Steele, Retired, EVP and CFO, Werner Enterprises

%
Program Savings
%
Personalized Therapy Review
%
Member Satisfaction
Download Case Study

Precision In Care

Discover VIVIO's technology-driven product suite, designed to enhance drug management with personalized care, transparency, and cost savings. Whether replacing your PBM or improving your current setup, VIVIO offers tailored products to meet your unique needs, delivering exceptional value in healthcare management.

Precision Care Drug Management

Full PBM replacement for all prescription drugs leveraging the Cash Pay marketplace.

40%+ Savings on Specialty Drug Spend

Precision Care Specialty Drug Management

30%+ Savings on Pharmacy Drug Spend

Full PBM replacement for specialty drugs including high-cost areas such as oncology, inflammation and HIV.

Precision Care Medical Drug Management

Medical specialty drug management (HCPCS codes).

50%+ Savings on Professionally Administered Specialty Drug Spend

Precision Care GLP-1

Clinically driven GLP-1 program to manage out of control spend on GLP-1s that works for any PBM plan.

40%+ Savings on Diabetes Drugs

How can VIVIO Help You?

VIVIO's PBM-replacement model offers a revolutionary way to manage drug costs, ensuring you achieve significant savings while improving outcomes. With VIVIO, you can trust that you're providing the best care for your employees while also protecting your organization from legal and compliance risks. Join us in transforming drug management for a healthier, more efficient future.

Lower Costs:

Save over 30% on Specialty and Full Rx combined with VIVIO's data-driven approach.

Benefit from fair marketplace pricing on all prescriptions, eliminating unnecessary markups and middlemen.

Better Outcomes:

Enhance prescribing accuracy with VIVIO's data intelligence, tailored to individual patient needs.

Improve employee health with personalized drug therapy recommendations, ensuring the right drug for the right patient at the right time.

Enhanced Compliance:

Meet fiduciary obligations with VIVIO's transparent and accountable model, reducing the risk of compliance issues.

Access comprehensive data to protect your organization and ensure you are making the best decisions for your employees' health and safety.

Stay Informed

Get the latest news impacting the Drug industry and how it impacts your company. Dive into our expert webinars and comprehensive guides designed to support your decision making.

View all resources

 

Open Markets, Better Outcomes, Lower Costs

A Discussion with Mark Cuban on Healthcare Innovation

 

Accumulation of Copay Card Usage for High Deductible Health Plans with HSAs

Research

Dive deeper into the topics explored by our team of experts. VIVIO clinicians publish research and articles pertaining to the latest news in healthcare.

ESMO 2024: Highlights and Analysis

Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

ecancer, 09/17/2024

Associate Professor Bishal Gyawali of Queen's University talks to ecancer at the 2024 ESMO Congress about his highlights from this year's conference.

Does FDA Withdrawal of Cancer Drug Show Bigger Changes Needed?

Neil Osterweil, Referencing Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

Oncology News Central, 03/12/2024

Although the FDA's accelerated approval policy is designed to help patients get access to promising drugs, some experts remain skeptical about certain aspects of the process. The recent withdrawal of a cancer drug has raised concerns among physicians about patient safety and drug efficacy.

Congressional Investigation of RevAssist-Linked and General Pricing Strategies for Lenalidomide

Kevin Knopf, MD, MBA, Director of Clinical Innovation, VIVIO

JCO Oncology Practice, 02/27/2024

Lenalidomide is an example of a drug whose financial success resulted from price increases and anticompetitive market strategies. We review tactics that led lenalidomide to become the third largest revenue-producing pharmaceutical product worldwide, with $12.2 US dollars (USD) billion sales in 2020, focusing on impact on patients and Medicare and developing policy recommendations.
High costs of drugs are not tightly correlated with value, and pricing decisions by many manufacturers are responsible for high costs, patient burden, and unsustainable pharmaceutical markets.

Perspectives on Cancer Therapy Development

William J.M. Hrushesky, MD, FACP, ABIM IM & MO, VIVIO Clinical Advisory Board

The Asco Post, 09/10/2023

I vividly recall a young veteran with a highly treatable and potentially curable cancer. We quickly reached what seemed a “fork in the road.” Two effective therapies were available: one inexpensive and generic and a second an equally good patented and expensive medicine. There was no evidence of superiority of either.
I informed him of the vast price difference and asked which he would prefer. This veteran did not hesitate for a second: “I will take the cheap one, doc…. I am not the only one in this foxhole.” This sentence broke my heart, and, to this day, its recall gives me goose flesh and unavoidable flowing tears. This intense and unforgettable experience, although long ago and far away, remains highly relevant to today’s cancer medicine.

The Accelerated Approval Program for Cancer Drugs — Finding the Right Balance

Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

The New England Journal of Medicine, 09/09/2023

The Food and Drug Administration (FDA) approves about two thirds of new cancer drugs on the basis of clinical trials that use surrogate end points, such as laboratory values or radiographic findings, rather than clinical end points that assess survival or how patients feel or function. The accelerated approval program allows drugs designed to treat serious conditions for which there is an unmet medical need to be approved on the basis of changes in surrogate measures that are only reasonably expected to predict clinical outcomes. Because in certain fields of medicine, such as cancer, a drug’s effects on surrogate measures such as tumor size (see table) are often more pronounced and occur more rapidly than effects on a patient’s clinical status, trials focused on surrogate measures can enroll fewer patients and can be completed more quickly than trials with clinical end points, thereby enabling products to reach the market earlier. Since clinical end points such as survival are generally what matter to patients, however, the FDA requires that the clinical benefits of drugs granted accelerated approval be confirmed in subsequent trials.

Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?

Daniel A. Goldstein, MD and Bishal Gyawali, MD, VIVIO Clinical Advisory Board

Journal of Clinical Oncology, 03/24/2023

The benefit of any treatment for any disease should be judged by whether it improves either survival or its quality. For adjuvant treatment of cancer, effects on overall survival (OS) are paramount: Patients and their oncologists are willing to accept substantial toxicity and short-term deficits in quality of life, if long-term survival can be improved. Assessment of the validity of randomized controlled trials (RCTs) evaluating adjuvant therapy requires that several questions about trial design and analysis be addressed.

Lowering Clinical Trial Standards for the Poor

Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

The Lancet, 12/26/2021

An increasing number of cancer clinical trials are conducted in low-and-middle-income countries (LMICs). Increasing the representation of LMICs in cancer drug trials is encouraging, but we are concerned about research parasitism and parachutism in these practices. In this commentary, we explore how LMICs may not have been served by participating in these global cancer drug trials.

Access to Cancer Medicines Deemed Essential by Oncologists in 82 Countries

Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

The Lancet, 09/21/2021

The WHO Essential Medicines List (EML) identifies priority medicines on the basis of a rigorous review of their benefits, harms, affordability, availability, and feasibility of delivery. The EML serves as a valuable tool for policy makers of member states to optimize country-level selection of medicines and to ensure access to these drugs in the context of universal health coverage (UHC). The EML can guide the procurement of medicines, favoring competition among treatments with overlapping benefits, and is the basis of the WHO Prequalification Programme and the Medicines Patent Pool.

The Burden of Out-of-Pocket Costs for NSCLC Care

Bishal Gyawali, M.D., VIVIO Clinical Advisory Board

MedPage Today, 04/09/2021

The more lung cancer patients had to pay out of pocket for treatment, the less likely they were to adhere to, or continue, therapy, reported researchers, who also found an indication of resulting less-than-ideal survival odds.

"I've done a lot of implementations in my career. VIVIO's was one of the easiest.

- Mike Adams, Vice President, Benefits & HR Systems, Dean Foods

Save Up to 30% on Your Total Drug Spend

Known for delivering excellence in Specialty Drug Management, VIVIO now offers Full Drug Management software to meet all of your members drug needs. Speak with us and we'll walk you through the best options for your company.

Speak With Us